ASP4345 + Matching Placebo
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Mar 28, 2016 โ Jun 8, 2017
NCT ID
NCT02720263About ASP4345 + Matching Placebo
ASP4345 + Matching Placebo is a phase 1 stage product being developed by Astellas Pharma for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02720263. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02720263 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia